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The gef gene has cell-killing functions in Escherichia coli. To evaluate the feasibility of using this gene as a new strategy for cancer
therapy, we transfected it in MCF-7 cells derived from breast cancer (MCF-7TG). The gef gene was cloned in a pMAMneo vector
under the control of a mouse mammary tumour virus promoter, inducible by dexamethasone (Dex), and was transfected with
liposomes. After selection and induction, expression of the gef gene was confirmed by reverse transcription–polymerase chain
reactions (RT–PCR) and Western blot. Cell viability was determined with a haemocytometre and the sulphorodamine B colorimetric
assay, and the cell cycle was studied by propidium iodide (PI) staining. Annexin V-FITC and PI assays were used to evaluate apoptosis,
which was confirmed by electron microscopy. In comparison with MCF-7 parental cells and MCF-7 cells transfected with an empty
vector, MCF-7TG cells induced with Dex showed a significant decrease in proliferation rate, which was associated with evidence of
apoptosis. Morphological findings confirmed apoptosis and showed a typical pattern of mitochondrial dilation. Furthermore, the cell
cycle was characterised by premature progression from G1 to Sphase and G2 delay. Our results show that the gef gene was able to
decrease proliferation in a breast cancer cell line, and induce apoptosis. These findings suggest that the gef gene is a potential
candidate for tumour therapy.
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There is an urgent need to develop novel systemic strategies for
patients with cancer. Gene transfer to tumour cells offers new
possibilities for cancer therapy based on the genetic modification
of tumour cells (Marchisone et al, 2000). Strategies based on
putative killer-suicide genes such as Herpes simplex virus
thymidine kinase and cytosine deaminase indirectly induce
cytotoxicity in mammalian cells. In both systems, the enzymes
encoded by suicide genes convert a nontoxic prodrug (ganciclovir
and 5-fluorocytosine, respectively) into a toxic metabolite
(Shangara et al, 2000), which causes DNA chain termination or
inhibits RNA and DNA synthesis during the S phase of the cell
cycle (Greco and Dachs, 2001). However, problems with the release
of toxic metabolites have led to the development of new strategies
for cancer therapy based on the use of toxic genes, which do not
need prodrugs to be effective in tumour cells. These promising
strategies aim to act directly on the cell cycle and cell proliferation
(Pietersen et al, 1999; Martin et al, 2000; Pu ¨tzer et al, 2000). The
expression of these genes is controlled by a significant number of
tumour tissue-selective promoters and enhancer elements that
have demonstrated their potential for use in gene therapy.
However, promoters with specific actions in different cancers will
need to be selected to realise the potential of this new therapeutic
approach (Hart, 1996; Shillitoe et al, 2000).
In this context, a number of genes have been identified as
members of a gene family that encodes homologous cell-killing
functions in Escherichia coli (Gerdes et al, 1990). In a member of
this family, named the gef gene (isolated from the chromosome of
E. coli) (Poulsen et al, 1991), the killing function is mediated by a
membrane protein of about 50 amino acids, which induces the
arrest of cellular respiration; subsequently, the cells undergo
morphological changes (characteristic ‘ghost’ cells) and become
nonviable (Poulsen et al, 1992). Previous studies have demon-
strated that Gef is anchored in the cytoplasmic membrane by the
N-terminal part of the protein, whereas the C-terminal part is
localised in the periplasm. Mutagenesis experiments with Gef
showed that the periplasmic portion of the gene encodes the toxic
domain, and that dimerisation is not essential for the toxic effect
(Poulsen et al, 1991). This effect was expressed in analyses with
suicide cassettes consisting of members of the gef gene family in
combination with inducible promoters (Molin et al, 1993). This
gene, currently being studied to determine its ability to control
bacterial population death (Ronchel and Ramos, 2001), may be a
new candidate for therapeutic applications.
In this study, we used a mammalian expression vector
containing the gef gene under the control of the mouse mammary
tumour virus (MMTV) promoter, inducible by dexamethasone
(Dex), to evaluate the expression, in vitro, of this gene in
tumoral MCF-7 cells derived from breast cancer. We found that
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sexpression of the gef gene in these tumoral cells significantly
decreased growth and induced apoptosis. These results suggested
the feasibility of using a gef gene system as a new strategy for
cancer therapy.
MATERIALS AND METHODS
Construction of gef expression vector
The gef gene (kindly provided by the Zaidı ´n Experimental Station,
CSIC, Granada, Spain) was subcloned into the mammalian
expression vector pMAMneo (Clontech, Palo Alto, CA, USA),
which allows Dex-inducible expression of cloned inserts. The full-
length gef insert, flanked at 30 and 50 by a XhoI and an NheI
restriction site, respectively, was amplified by polymerase chain
reaction (PCR) with routine DNA manipulation (Sambrook et al,
1989). The PCR product was double-digested with NheI and XhoI
and inserted into pMAMneo, and this construction was used to
transform E. coli. The cells were plated onto Luria–Bertani broth
plates containing ampicillin. A single insert-positive clone (with
pMAMneo-gef) was selected for transfection into MCF-7 cells after
analysis by restriction-enzyme digestions and PCR to establish
reading frame orientation and sequence fidelity.
Cell culture and stable transfection
The human breast cancer MCF-7 cell line was kindly provided by
Dr N Olea of the Sa ´nchez Mora Tumoral Biology Institute,
University Hospital of Granada. MCF-7 cells were grown at 371Ci n
an atmosphere containing 5% CO2, with Dubelcco’s modified
Eagle’s medium (DMEM) (Gibco, Grand Island, NY, USA)
supplemented with 10% heat-inactivated foetal bovine serum
(FBS) (Gibco), 2% L-glutamine, 2.7% sodium bicarbonate, 1%
Hepes buffer, 40mgl
 1 gentamicin and 500mgampicillin
 1.T o
isolate stably transfected cells, 2 days before transfection confluent
MCF-7 cells were split 1:5 into six-well plates, yielding approxi-
mately 70% confluence on the day of transfection. The cells were
washed with culture medium, then transfected using 6ml FuGENE
6 reagent (Roche Diagnostic, Barcelona, Spain) with 1.8mg per well
of pMAMneo empty vector or pMAMneo-gef in 2ml of culture
medium. After 48h, the medium was replaced with selective
medium: DMEM, 10% FBS, 500mgml
 1 geneticin G418 (Sigma, St
Louis, MO, USA), and resistant clones were selected. Single clones
of stably transfected cells, isolated by limiting dilution in 96-well
plates, were transferred to individual flasks and cultured in
medium containing 300mgml
 1 G418. For the present study, a
clone named MCF-7TG (MCF-7 cells transfected with pMAMneo-
gef gene) was used. Integrity of the transfected vector sequence in
the MCF-7 cells was analysed by PCR. Genomic DNA was extracted
from MCF-7 parental and MCF-7TG cells with the Magict
Megapreps DNA Purification System (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. Total DNA
(250ng) was diluted to 50ml in a mixture with a final
concentration of 250mM dNTP, 100ng of each primer, 5mlP C Rb u f f e r
and 2.5U Taq polymerase (Roche Diagnostic). The primers used were
Gef 3: 50GAAGCAGCATAAGGCGATG30 and Gef 4: 50CTCGG
ATTCGTAAGCCGTG30. Polymerase chain reaction (941Cf o r5 m i n ,
611Cf o r1m i na n d7 2 1C for 1min) was carried out for 32 cycles with a
final elongation step of 721C for 10min. For analysis, 10mlo ft h e
reaction product was run on a 2% agarose gel, visualised by ethidium
bromide staining and photographed under ultraviolet light.
Reverse transcription (RT)–PCR and Western blot analysis
For RT–PCR analysis, total RNA was extracted from MCF-7 and
MCF-7TG cells after 24h of induction with Dex with an RNA
extraction kit (Promega) according to the manufacturer’s instruc-
tions. RNA (1mg) from each cell line was then reverse-transcribed
into cDNA using a first-strand cDNA synthesis kit (Promega). PCR
of the RT was done and analysed under the same condition as
detailed above, using 5ml of the RT products. The integrity of RNA
was assessed by amplification of b-actin mRNA using 50-primer nt
1854–1873 and 30-primer nt 2151–2170 (Prados et al, 1998). For
Western blot analysis, we used a polyclonal antibody against the
Gef protein that was produced at the Technical Service of the
University of Seville (Seville, Spain) by immunising rabbits with a
25 amino-acid synthetic peptide (carboxy terminus of the protein)
predicted from the DNA sequence of the gef gene (Poulsen et al,
1991). Total proteins were obtained from MCF-7 and MCF-7TG
cells after induction for 24h with Dex. The cells were harvested
and lysed in sample buffer consisting of 62.5mM Tris HCl (pH 6.8),
10% glycerol, 2% SDS, 5% 2-mercaptoethanol, 0.5% bromophenol
blue and 100mM dithiothreitol. Proteins were separated on 15%
SDS–polyacrylamide gels and electroblotted onto Immobilon-P-
membranes (Millipore, Bedford, MA, USA). Blocking, washing,
and incubations of the blotted nitrocellulose membranes were
carried out as described (Prados et al, 1995). The polyclonal
antibody against the Gef protein was diluted 1:10, and positivity
was detected with an anti-rabbit IgG peroxidase conjugate (Sigma).
Cell proliferation assays
MCF-7 and MCF-7TG cells (25 10
3) were plated into six-well
plates under the culture conditions detailed above. After 24h, cells
were fed with fresh medium and treated with 1mM Dex (Sigma) to
induce the promoter activity of MMTV. In the control groups, cells
were not treated with dexamethasone. To verify that Dex had no
effect on cell growth, MCF-7 parental cells were also treated with
Dex. The cultures were fed with fresh medium with or without Dex
every alternate day up to the end of the experiment; each treatment
and time point was run in four plates. After 1, 2, 4, 6, 10 and 15
days of treatment, cells were trypsinised, collected, and counted
with a haemocytometre. Trypan blue dye exclusion was used to
determine cell viability. The same experiment was performed using
the sulphorodamine-B (SRB) colorimetric assay as described
previously (Villalobos et al, 1995), with a Titertek Multiscan
apparatus (Flow, Irvine, CA, USA) at 492nm. We evaluated
linearity of the colorimetric results with cell number for each MCF-
7 cell stock before each cell growth experiment. MCF-7 cells
transfected with pMAMneo empty vector were used in the
proliferation assay as a control.
Apoptosis detection by staining with annexin V-FITC and
propidium iodide (PI)
The Annexin V-FITC Apoptosis Detection Kit I (Pharmingen, San
Diego, CA, USA) was used to detect apoptosis by flow cytometry.
MCF-7TG cells (1 10
6 cells) were plated onto 75-cm
2 flasks and
cultured overnight, followed by incubation with Dex for 48 and
96h. MCF-7 parental cells and MCF-7TG cells were harvested by
phosphate-buffered saline-ethylenediamine-tetraacetic acid (PBS-
EDTA), washed twice in cold PBS (1.4 M NaCl, 27mM KCl, 100mM
KH2PO4/K2HPO4, pH 7.2), and pelleted by centrifugation at 500g
for 10min. They were then resuspended at 10
6 cells100ml
 1 in a
binding buffer (Hepes buffer, 10mM, pH 7.4, 150mM NaCl, 5mM
KCl, 1mM MgCl2, 1.8mM CaCl2), stained with annexin V
incubation reagent (1ml annexin V-FITC (25mgml
 1), 10ml
binding buffer, 10ml PI (50mgml
 1,7 9 mlH 2O) and incubated in
the dark for 15min at room temperature. Then, 500ml binding
buffer was added and the cells (10000 cells per sample) were
immediately processed with a FACScan flow cytometre (Becton
Dickinson, San Jose, CA, USA).
Ultrastructural analysis
Adherent and nonadherent MCF-7 parental cells and MCF-7TG
cells treated with Dex during 48 and 96h were fixed with 2.5%
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sglutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 1h at
room temperature. The pellet and monolayer were postfixed with
1% osmium tetroxide in 0.1 cacodylate buffer for 1h at room
temperature, and dehydrated in ethanol. Cells were detached from
the culture vessel by rapid treatment with propylene oxide and
embedded in Epon 812. After polymerisation, the plastic was
removed and ultrathin sections were cut parallel and perpendicular
to the surface of the flask. The sections were contrasted with uranyl
acetate–lead citrate and examined in a Hitachi H7000 transmis-
sion electron microscope.
Cell cycle analysis
Cells in monolayer culture were harvested, washed twice with
sample buffer (100mg glucose; 100ml PBS without Ca
2þ or
Mg
2þ) and fixed in 70% (volvol
 1) cold ethanol for up to 1 week.
Cells were pelleted, washed once with sample buffer and
resuspended in PI solution (50mgml
 1 PI, 0.5mgml
 1 RNase in
sample buffer, pH 7.4) for 30min in the dark. Fluorescence-
activated cell sorter analysis was performed 48 and 96h after
induction. The data from 10000 cells per sample were collected
and analysed using the Cellfit program on a FACScan flow
cytometre (Becton Dickinson, San Jose, CA, USA).
Statistical analysis
All statistical analyses were carried out with the SPSS, release 7.5
(SPSS, Chicago, IL, USA). The results were compared with
Student’s t-test. All data are expressed as the mean7s.d. The
differences were considered statistically significant at a P-value of
o0.05.
RESULTS
Gef protein expression in MCF-7 transfected cells
To analyse the effect of the gef gene in tumoral cells, MCF-7 cells
were transfected with the pMAMneo inducible vector containing
the gef sequence. The presence and integrity of DNA from the gef
gene in MCF-7 transfected cells (MCF-7TG) was assessed by PCR
with genomic DNA (data not shown). The gene was expressed in
cultures of MCF-7TG cells that contained Dex, but not in those
without Dex. The presence of mRNA from the gef gene in MCF-
7TG cells was verified by RT-PCR (Figure 1). Western blot analyses
were performed to determine the presence of the Gef protein in
MCF-7TG cells. The results of immunoblotting with the polyclonal
antibody against the Gef protein were consistent with the RT–PCR
results (Figure 1).
Modulation of growth pattern in MCF-7 transfected cells
We found no significant differences in growth patterns between
MCF-7 parental cells with or without Dex treatment and MCF-7
cells transfected with pMAMneo empty vector. In MCF-7 cells
transfected with gef and treated with Dex, the decrease in
proliferation rate in comparison with parental MCF-7 was first
observed on day 4 of induction, became significant by day 6, and
was obvious by day 10 of culture (Figure 2). After 48h of
induction, growth was not inhibited in MCF-7TG cells compared to
MCF-7 parental cells or those transfected with empty vector.
At 6 days, however, MCF-7TG cells incubated with 1mM
Dex showed a 34.4% decrease in growth (Po0.001) with
respect to control cultures. After 10 and 15 days of incubation
with Dex, growth was inhibited by 75 and 67.9%, respectively
(Po0.001).
Apoptosis in MCF-7 transfected cells
Simultaneous staining with annexin V-FITC and IP nonvital dye
made it possible to distinguish between intact cells (stained
negative for both annexin V-FITC and PI), early apoptosis (stained
positive for annexin V-FITC and negative for PI), and late
apoptosis or cell death (stained positive for both and annexin V-
V-FITC and PI). In our MCF-7 control culture, 80.12% of the cells
were viable, 8.13% were in early apoptosis, and 9.15% were in the
late or final stages of apoptosis (Po0.001) (Figure 3a). Initial
analysis of MCF-7 cells induced with Dex during 12 and 24h
showed no significant modification in relation to the control
culture (data not shown). However, in MCF-7TG cells treated with
Dex during 48h, 14.32% of the cells were viable, 45.02% were in
1    2 34M W
248 pb
MW (kDa)
12 3 4
170 bp
48
34
28
21
12
A
B
C
Figure 1 Determination of gef gene expression by RT–PCR and
immunoblot. Total RNA isolated from MCF-7 parental and MCF-7TG cells
was transcribed to cDNA using reverse transcriptase. Polymerase chain
reaction amplification of cDNA was performed as described in Materials
and Methods. The amplified PCR product of gef mRNA (a) and b-actin
mRNA (b) were separated by 2% agarose gel electrophoresis and
visualised with ethidium bromide. (A) Lane 1, MCF-7; lane 2, MCF- 7TG;
lane 3, pMAMneo-gef (positive control). (B) Lane 1, MCF-7; lane 2, MCF-
7TG; lane 3, pMAMneo-gef (negative control). (C) Western blot analyses
of total proteins prepared from MCF-7 parental and MCF-7TG cells were
performed with a polyclonal antibody against the Gef protein. Lane 1, MCF-
7; lane 2, MCF-7TG. MW, molecular weight VIII.
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searly apoptosis and 33.37% were in the late or final stages of
apoptosis (Figure 3b). In MCF-7TG cells treated with Dex for 96h,
the corresponding figures were 8.90, 51.81 and 36.85% (Po0.001)
(Figure 3c).
Morphological analysis of MCF-7 transfected cells
Light microscopic observations showed modifications in the
morphology of MCF-7TG cells after induction with Dex, char-
acterised by rounding and loss of adherence to the flask (Figure 4).
MCF-7 cells transfected with empty vector showed no morpholo-
gical changes in comparison with the parental cell line. Moreover,
Dex had no effect on the morphology of MCF-7 parental cells (data
not shown). However, the death of MCF-7TG cells by apoptosis,
which appeared after 48h of Dex treatment, was clearly confirmed
in ultrastructural images. In the cell nucleus, the earliest
recognisable cytological changes were compaction and segregation
of the chromatin at the nuclear periphery. Initially, the fine
structure of this chromatin was similar to that of condensed
chromatin clumps in healthy cells, with the granular appearance of
cross-sectioned chromatin fibres being clearly visible (Figure 5b).
At more advanced stages of apoptosis, progression of chromatin
compaction was associated with redistribution of chromatin fibres,
resulting in electron-dense domains of degraded homogeneous-
appearing chromatin. In some instances compaction and degrada-
tion of chromatin occurred in association with convolution of the
nuclear profile (Figure 5c). Another important feature within the
nucleus of apoptotic cells was the reorganization of ribonucleo-
protein-containing structures, including the nucleolus. Compac-
tion and marginalisation of the chromatin produced clear
nucleoplasmic areas in the nucleus (Figure 5c). In the cytoplasm,
we observed dilated mitochondria (Figure 5d).
Modulation of cell cycle in MCF-7 transfected cells
Parental cell cultures contained 74.98% G1/G0 cells, 12.83% S-
phase cells and 12.19% G2/M-phase cells. In contrast, after 48h of
Dex induction, MCF-7TG cells showed a gradual disappearance of
G1-phase cells and a corresponding accumulation of S-phase cells.
After 96h of induction, the increase in the S-phase population
(37.20%) and decrease in the number of G1 phase cells (60.53%
G1/G0 cells) and G2/M-phase cells (2.45%) were even more marked
(Figure 6).
DISCUSSION
We demonstrate for the first time that transfection of the gef gene
makes it possible to decrease tumour cell growth in breast cancer
cell line MCF-7. Our system is independent of the administration
of a prodrug, which is required in systems such as Herpes simplex
virus thymidine kinase and cytosine deaminase (Greco and Dachs,
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Figure 2 Determination of the effects of gef gene expression on cell
proliferation. MCF-7 parental cells, MCF-7 cells induced with Dex (MCF-
7Dex), MCF-7TG cells induced with Dex (MCF-7TGDex) and MCF-7 cells
transfected with empty vector (MCF7-pMAMneo) were seeded at
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Figure 3 Quantification of gef-induced apoptosis in MCF-7TG cells by
fluorescence-activated cell sorting analysis. Cells were stained with annexin
V and PI to evaluate apoptotic cell death, as described in Materials and
Methods. (A) MCF-7 cells. (B) MCF-7TG cells after 48h of induction with
Dex. (C) MCF-7TG cells after 96h of induction with Dex. The data shown
are representative of three separate experiments.
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s2001), and which may present problems related to general toxicity,
drug release and bioviability.
The use of genes that damage tumour cells and do not require a
prodrug is one of the aims of new gene therapy strategies.
Recently, some procaryotic and viral genes have been shown to be
able to induce tumour cell death (Martin et al, 2000; Zhuang et al,
1995; Paulus et al, 1997). In this connection, the gef gene shows a
killing function in procaryotic cells, which may be modulated by
the action of different promoters (Molin et al, 1993). The product
of the gef gene is a cytoplasmatic membrane protein whose 19 N-
terminal hydrophobic amino acids constitute a membrane-
spanning segment, probably in the form of an alpha-helix structure
that anchors the protein to the membrane. The C-terminal part,
localised in the periplasm in dimeric form, encodes the toxic
domain (Poulsen et al, 1991). We used a eucaryotic expression
vector that includes the MMTV promoter to obtain a construction
with the gef gene. Transfection of this construct into MCF-7 cells
and the induction of these tumoral cells with Dex led to a marked
decrease in the rate of cell growth in MCF-7TG cells in comparison
with parental MCF-7 cells. This finding suggests that the gef gene
has an antiproliferative effect on breast cancer cells.
Although the gef gene showed considerable cytotoxic effects in
MCF-7 cells, it is not clear how this gene inhibits growth of these
tumour cells. Nonmammalian genes may act through different
mechanisms when they are introduced and expressed in tumour
cells. However, the induction of apoptosis in tumour cells is a
frequent mechanism of cell damage. Gene therapy strategies based
on the use of diphtheria toxin A gene (Paulus et al, 1997) have
achieved complete inhibition of protein synthesis in glioblastoma
cells. The chicken anaemia virus-derived protein VP3 (apoptin) is
able to induce programmed cell death in transformed and
malignant cells, including osteosarcoma cells (Zhuang et al,
1995; Pietersen et al, 1999). In melanoma, tranfection of the
transcription factor E2F-1 induced apoptosis in the tumoral cell
lines SK-MEL-28 and SK-MEL-2 (Dong et al, 1999). To determine
whether apoptosis is also the mechanism by which the gef gene
induces cytotoxicity, MCF-7TG cells were stained with annexin V
and PI, and examined with fluorescence-activated cell sorting.
These studies clearly demonstrated that cytotoxicity was the result
of induction of apoptotic cell death. However, apoptosis was
clearly demonstrated after 48h of induction, in contrast to what
has been observed in procaryotic cells such as Pseudomonas putida
(Ronchel et al, 1998). In procaryotic cells, widespread cell death
occurred 7h after induction. This may reflect structural and
functional differences between human and bacterial cell mem-
branes or to the need for a target amount of Gef protein in the
eucaryotic cells. This latter requirement has been observed in
procaryotic cells, in which a critical concentration of Gef protein
(different from other killer proteins such as protein E) was needed
Figure 4 Phase contrast micrographs of parental and transfected MCF-7
cells. Parental MCF-7 cells, grew in clumps, were typically polygonal in
outline ( 40) (A) and adhered strongly to the culture flask, whereas MCF-
7TG cells treated with Dex for 48h ( 40) (B) to induce gef gene
expression were rounded and easily detached from the culture flask. These
changes were more marked in MCF-7TG cells after 96h of Dex induction
( 20) (C).
Figure 5 Ultrastructural morphology of MCF-7 and MCF-7TG cells
treated with Dex to induce gef gene expression. (A) Typical morphology
of MCF-7 parental cells demonstrated light cytoplasmic complexion
( 2500). (B) MCF-7TG cell with condensed granular-appearing chroma-
tin ( 4000). (C) Dying MCF-7TG cell with a convoluted nuclear
membrane. The masses of compact chromatin are highly electron dense
and homogeneous in texture. Note mininuclei with a different chromatin
pattern ( 6300). (D) Detail of cytoplasm of an MCF-7TG with
mitochondrial dilation ( 8000). Scale bars: (A) 2.4mm; (B) 1.5mm; (C)
0.9mm; (D) 0.75mm.
A: G0-G1: 74.98%
S:12.83%
G2-M: 12.19%
B:G0-G1: 63.19%
S:27.09%
G2-M: 9.72%
C:G0-G1: 60.35%
S:37.20%
G2-M: 2.45%
Figure 6 FACScan analysis of the cell cycle. MCF-7 and MCF-7TG cells
treated with Dex were harvested and analysed to distinguish populations of
cells in different phases of the cycle, as described in Materials and Methods.
(A) Parental MCF-7 cells. (B) Transfected MCF-7TG cells after 48h of Dex
induction. (C) Transfected MCF-7TG cells after 96h of Dex induction.
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sto provoke cell death (Ronchel et al, 1998). In MCF-7TG, apoptosis
was confirmed in electron microscopic images. The most
significant finding was the compaction and marginalisation of
chromatin at the nuclear periphery, which is a cytological hallmark
of apoptosis (Kerr et al, 1995). Similar changes have been observed
during apoptotic cell death in MCF-7 cells transfected with
antisense Hsp70 cDNA (Nylandsted et al, 2000).
In procaryotic cells, it has been shown that the product of the gef
gene is anchored to the cell membrane, where it diminishes the
membrane potential and leads to membrane leakiness, which in
turn results in the efflux of cellular Mg
2þ and the influx of
periplasmic molecules (Gerdes et al, 1986). This mechanism
induces morphological changes in cells, which subsequently
undergo cell death (Ono et al, 1987). The specific mechanisms of
action of the gef gene in eucaryotic cells have not been elucidated.
Nonetheless, two of our findings stand out. Firstly, cell cycle
analysis in MCF-7TG cells suggested that gef gene expression is
associated with aberrant cell cycle control characterised by
premature progression from G1 to S phase and G2 delay. The
results of cell cycle analysis are consistent with those in other
tumour cell lines in which apoptotic mechanisms have been
induced (Wei et al, 1998). Since they are unable to accomplish
normal mitosis, these cells do not proliferate, and apoptotic cell
death is induced. Secondly, we also observed a typical pattern of
mitochondrial dilation that was always present in all MCF-7TG
cells analysed after gef expression was induced. This finding may
be related to the induction of apoptosis by the gef gene, and may
also be related to the alteration in mitochondrial membranes,
which has been demonstrated to be a critical step in several
apoptotic pathways (Boya et al, 2001). However, although
numerous models of apoptosis have been described in tumour
cells (e.g., calcium-binding proteins, protein kinases, nuclear
transcription factors, oncogenes and cysteine proteases) (Rowan
and Fisher, 1997; Favrot et al, 1998), the pathway by which the gef
gene acts in MCF-7 cells presently remains under investigation.
To our knowledge, this is the first demonstration that the gef
gene, which has a killing function in E. coli, significantly impairs
proliferation in tumoral MCF-7 cells derived from breast cancer.
Although the mechanism remains unknown at present, it is clear
that the product of the gef gene induces cellular modifications that
are representative of apoptosis in these tumour cells. Our results
suggest that the gef gene can be considered a possible candidate for
a new gene therapy strategy, which is simpler than other killer-
suicide systems because it does not require the use of a prodrug.
The possibility of using selective transcriptional control sequences
with gef therefore offers the gene therapist a tool of significant
potential. We are carrying out experiments in mice and in other
tumoral cells which can determine the effectiveness of this new
cancer therapy approach.
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